(2018) found significant reductions in the risk of major cardiovascular events associated with an SBP target of less than 130 mm Hg.[57] The largest individual study to date examining SBP targets, the Systolic Blood Pressure Intervention Trial (SPRINT), included HTN patients age 50 and over and demonstrated a 25% reduction in cardiovascular events in the intensive treatment group targeting an SBP of 120 mm Hg.[58] Only a small proportion of SPRINT participants (those with known CVD) would have been included in the SR by Saiz et al. (2018),[55] which could perhaps explain why Saiz et al. (2018) did not find benefits for reducing SBP below 150 mm Hg. Specifically for HTN patients with diabetes, the SR and meta-analysis by Brunstrom et al. (2017) suggests that benefit of treatment in patients with diabetes may be limited to those with a baseline SBP of >140 mm Hg or to an achieved SBP of 130-140 mm Hg.[59] Overall, the available evidence was primarily for patients with type 2 diabetes with very limited evidence for those with type 1 diabetes. As shown by the SR by Ettehad et al. (2016), the proportional reduction in the rates of cardiovascular outcomes resulting from a 10 mm Hg reduction in blood pressure did not differ among people with prior cardiovascular disease (CVD) events, coronary heart disease (CHD), CHF, or cerebrovascular disease.[54] Two other SRs specifically examined the risk of stroke recurrence among patients receiving more intensive HTN therapy.[60,61] These SRs also suggested a reduction in stroke recurrence based on additional HTN therapy. For many patients, benefits of intensive therapy seem to outweigh harms.